COMMUNIQUÉS West-GlobeNewswire

Notice to Convene the Annual General Meeting of Genmab A/S
18/02/2026
Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 19, 2026 [...]
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
18/02/2026
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer [...]
Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform
18/02/2026
Worcester, Massachusetts, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST ), a diversified innovation company with operations spanning eco-friendly products and collectibles monetization, today [...]
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
18/02/2026
- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - Rasayana to [...]
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
18/02/2026
MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, [...]
Genelux Corporation to Participate in Upcoming Conferences
18/02/2026
WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming [...]
Design Therapeutics to Participate in Upcoming Investor Conferences
18/02/2026
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that [...]
Health Systems and Strategic Partners Unite to Address Widening Healthcare Gaps in Rural and Underserved Communities
18/02/2026
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The National Specialty Care Access Coalition (NSCAC), a collaboration of more than 20 major US health systems, today announced its launch to address the growing breakdown in [...]
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
18/02/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient [...]
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
18/02/2026
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA [...]
Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
18/02/2026
Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment for psoriasis, vitiligo, and atopic dermatitis HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: [...]
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
18/02/2026
WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics
18/02/2026
Collaboration will harness UNP’s AI enhanced macrocycle platform to drug historically “undruggable” targets SANTA CRUZ, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing [...]
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
18/02/2026
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A mutation, supporting [...]
Olympia Pharmaceuticals Unveils Circulate, Expanding Its Single-Dose IV Nutritional Therapy Line
18/02/2026
New vascular health formula designed with blood flow and cellular energy in mind through a streamlined, ready-to-use delivery system ORLANDO, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a leader in [...]
Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
18/02/2026
Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare Market Simple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes IRVINE, Calif., Feb. 18, [...]
Alembic Therapeutics LLC Announces the Launch of PIVYA® (pivmecillinam)
18/02/2026
Pivya ® (pivmecillinam) Tablets, 185mg Now Available by Prescription in the United States BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics is pleased to announce the U.S. availability of Pivya [...]
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
18/02/2026
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
18/02/2026
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung Cancer Trial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA [...]

Pages